Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses
Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses
复制标题
DOI：
10.1016/s1570-9639(02)00547-2
复制
发表时间：
2003-03-21
影响因子：
3.2
通讯作者：
Seliger, B
中科院分区：
文献类型：
--
作者：
Lichtenfels, R;Kellner, R;Seliger, B
PROTEOMEX是一种将常规蛋白质组分析与血清学筛查相结合的方法，是分离蛋白质和鉴定恶性疾病中免疫原性组分的有力工具。通过应用这种方法，我们的特点是九个代谢酶的差异表达在肾细胞癌（RCC）细胞系，并比较其表达谱的正常肾上皮细胞。这些蛋白质，超氧化物歧化酶（SODC），丙糖磷酸酶异构酶（TPIS），硫氧还蛋白（THIO）和泛素羧基末端水解酶（UBL 1）的组成和干扰素（IFN）-γ诱导的蛋白质表达模式在细胞系或组织标本来源于RCC或正常肾上皮细胞，分别使用Western印迹分析和免疫组化进行了进一步分析。除了RCC细胞系MZ 1940 RC完全缺乏UBL 1的表达外，在RCC和正常肾上皮中检测到不同代谢酶的异质性和可变表达模式。在RCC细胞系中发现THIO表达水平的最高差异，与自体正常肾上皮相比，THIO表达水平上调2倍。此外，IFN-γ处理不影响这些代谢酶的组成型表达。因此，PROTEOMEX代表了一种有价值的方法，用于鉴定可能用作RCC诊断标志物的代谢酶。(C)2002 Elsevier Science B.V保留所有权利。
PROTEOMEX, an approach which combines conventional proteome analysis with serological screening, is a powerful tool to separate proteins and identify immunogenic components in malignant diseases. By applying this approach, we characterized nine metabolic enzymes which were differentially expressed in renal cell carcinoma (RCC) cell lines and compared their expression profiles to that of normal kidney epithelium cells. Four of these proteins, superoxide dismutase (SODC), triosephosphatase isomerase (TPIS), thioredoxin (THIO) and ubiquitin carboxyl-terminal hydrolase (UBL1) were further analysed for both their constitutive and interferon (IFN)-gamma inducible protein expression pattern in cell lines or tissue specimens derived from RCC or normal kidney epithelium using Western blot analysis and immunohistochemistry, respectively. With the exception of the RCC cell line MZ1940RC, which completely lacks the expression of UBL1, a heterogeneous and variable expression pattern of the different metabolic enzymes was detected in RCC and normal renal epithelium. The highest differences in the expression levels were found for THIO in the RCC cell lines, which was 2-fold upregulated when compared to autologous normal kidney epithelium. Moreover, IFN-gamma treatment did not influence the constitutive expression of these metabolic enzymes. Thus, PROTEOMEX represents a valuable approach for the identification of metabolic enzymes which might be used as markers for the diagnosis of RCC. (C) 2002 Elsevier Science B.V All rights reserved.